Join to View Full Profile
400 Parnassus AveSan Francisco, CA 94143
Phone+1 415-353-2421
Dr. Schoenbeck is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2021- University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2017 - 2020
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2012 - 2015
Oregon Health and Science University School of MedicineClass of 2012, MD
Certifications & Licensure
CA State Medical License 2015 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
Publications & Presentations
PubMed
- HSR25-174: Impact of Adverse Events on Quality of Life in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors - Results From the Survey on H...Kathryn E Flynn, Joan Clements, Karen DeMairo, Jennifer Hiller, David Wei
Journal of the National Comprehensive Cancer Network. 2025-03-28 - HSR25-182: Patient-Physician Communication About Adverse Events and Impact on Quality of Life to Foster Shared Decision-Making in Chronic Myeloid Leukemia.Kathryn E Flynn, Joan Clements, Karen DeMairo, Jennifer Hiller, David Wei
Journal of the National Comprehensive Cancer Network. 2025-03-28 - Frailty measures in multiple myeloma: evaluating the impact on outcomes and quality-of-life in clinical trials and real-world practice.Matthew J Pianko, Hira S Mian, Kelly L Schoenbeck, Tanya M Wildes
Leukemia & Lymphoma. 2025-02-01
Abstracts/Posters
- Cognitive Dysfunction Associated with Tyrosine Kinase Inhibitors in Patients with CML in Chronic PhaseKelly L. Schoenbeck, MD, Sirisha Tummala, MD, Neha G. Goyal, PhD, Catherine C. Smith, MD and Neil P. Shah, MD, PhD, 62nd American Society of Hematology Annual Meeting & Exposition, 12/6/2020
- Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative NeoplasmsKelly L. Schoenbeck, MD , Giselle Salmasi, MD , Miguel Carlos Cerejo, DO , Patricia A. Cornett, MD , Lloyd E. Damon, MD , Aaron C. Logan, MD PhD , Rebecca L. Olin, MD ..., 61st American Society of Hematology Annual Meeting & Exposition, Orlando, FL, 12/7/2019
Press Mentions
Clinical Challenges: Discontinuing TKIs in Chronic Myeloid LeukemiaDecember 11th, 2020
Program Chairs Pick Their Top ASH HighlightsDecember 1st, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
